Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News


2023 Psychedelic Industry Predictions, w/ Dustin Robinson of Iter Investments

Join Dustin Robinson of Iter Investments as he sets expectations for this year in psychedelics. During this event, he’ll cover research, business trends, and capital and regulatory markets. If you’re planning on participating in the psychedelics industry this year, you won’t want to miss this. Investing in Nucleus For those who don’t know, Nucleus currently…

psyc Press

PSYC Provides Shareholders with Key Corporate Updates and Highlights Objectives for 2023

PSYC Corporation (OTC Pink Market: PSYC), parent company to Spotlight Media Corporation, a multimedia leader positioned at the intersection where all things psychedelics and cannabis converge, is pleased to provide its shareholders with an overview of recent key corporate updates along with insight into some of the prime objectives the Company is outlining for the year ahead. Sacha…


The Future of Ketamine Telehealth When Biden Ends the Covid-19 Emergencies in May 2023

The Biden administration recently announced its plans to end the COVID Public Health Emergency (“PHE”) on May 11, 2023. This announcement has left many wondering what this means for the dozens of ketamine telehealth companies that were launched under an exception created by the PHE. Under the Ryan Haight Act, a controlled substance, such as…

Silo Pharma Press

Silo Pharma Announces Stock Repurchase Program

 Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1,000,000 of the Company’s common stock. The Company may purchase common stock in the open market, through privately negotiated transactions, or otherwise, in…

Clearmind Press

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Clearmind Medicine Inc. (NASDAQ: CMND | CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a…

BetterLife Pharma Press

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

BetterLife Pharma Inc (CSE: BETR | OTCQB: BETRF | FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the engagement of Bloom Burton Securities Inc. (“Bloom Burton”) for strategic advisory services to support BetterLife’s growth and development initiatives towards clinical trials. “We are very excited to be working…


FSD Pharma Inc. Commences Recruitment in FSD201 Phase 2 Clinical Trial

FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that recruiting is underway for its phase 2 trial of FSD201 for the treatment of chronic pain associated with idiopathic MCAS…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.